How support cells and their tiny antennae help repair myelin after white matter injury

Mechanisms of oligodendroglial ciliary function in white matter injury repair

NIH-funded research University of California, San Francisco · NIH-11318897

This project looks at how support cells called oligodendrocyte precursor cells and their tiny antenna-like structures help rebuild the protective myelin coating after white matter injury in conditions like multiple sclerosis and some newborn brain injuries.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco NIH-funded
Lab location1 site (San Francisco, United States)
Project IDNIH-11318897 on NIH RePORTER

What this research studies

Researchers at UCSF will study oligodendrocyte precursor cells (OPCs) and the primary cilia—small antenna-like structures—that help OPCs sense signals in damaged white matter. They will use genetic tools to remove or alter cilia in lab models and trace a signaling pathway (GPCR → cAMP → CREB) that appears to control OPC recruitment and myelin repair. Advanced proximity-labeling and molecular mapping will identify proteins and signals at the cilium that guide OPC behavior. The goal is to find points where future therapies could help OPCs reach injury sites and rebuild myelin.

Who could benefit from this research

Good fit: People affected by white matter damage such as adults with multiple sclerosis or individuals with white-matter injury-related cerebral palsy would be the most relevant patient groups for eventual therapies stemming from this work.

Not a fit: Patients whose conditions are driven mainly by non-white-matter problems or whose damage is too advanced for remyelination are less likely to benefit directly from this research.

Why it matters

Potential benefit: If successful, this work could point to new targets or treatments that help OPCs remyelinate damaged white matter, potentially improving recovery and slowing progression in diseases like multiple sclerosis and some forms of cerebral palsy.

How similar studies have performed: Prior preclinical work shows that enhancing OPC function can improve remyelination in animal models, but targeting primary cilia and the GPCR/cAMP/CREB signaling axis is a newer, largely preclinical approach.

Where this research is happening

San Francisco, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.